TW201696B - - Google Patents
Download PDFInfo
- Publication number
- TW201696B TW201696B TW081103831A TW81103831A TW201696B TW 201696 B TW201696 B TW 201696B TW 081103831 A TW081103831 A TW 081103831A TW 81103831 A TW81103831 A TW 81103831A TW 201696 B TW201696 B TW 201696B
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- mixture
- fat
- compounds
- mixtures
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 73
- 239000000203 mixture Substances 0.000 claims abstract description 39
- 239000004005 microsphere Substances 0.000 claims abstract description 30
- 241001465754 Metazoa Species 0.000 claims abstract description 22
- 241000244206 Nematoda Species 0.000 claims abstract description 15
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 14
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 13
- 239000000194 fatty acid Substances 0.000 claims abstract description 13
- 229930195729 fatty acid Natural products 0.000 claims abstract description 13
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 11
- YNFMRVVYUVPIAN-UHFFFAOYSA-N nemadectin alpha Natural products C1C(O)C(C)C(C(C)=CC(C)C)OC11OC(CC=C(C)CC(C)C=CC=C2C3(C(C(=O)O4)C=C(C)C(O)C3OC2)O)CC4C1 YNFMRVVYUVPIAN-UHFFFAOYSA-N 0.000 claims abstract description 9
- 208000015181 infectious disease Diseases 0.000 claims abstract description 8
- YNFMRVVYUVPIAN-AQUURSMBSA-N nemadectin Chemical compound C1[C@H](O)[C@H](C)[C@@H](C(/C)=C/C(C)C)O[C@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 YNFMRVVYUVPIAN-AQUURSMBSA-N 0.000 claims abstract description 8
- 241000238421 Arthropoda Species 0.000 claims abstract description 7
- 238000007911 parenteral administration Methods 0.000 claims abstract description 7
- 230000002265 prevention Effects 0.000 claims abstract description 3
- 239000003925 fat Substances 0.000 claims description 28
- 239000003921 oil Substances 0.000 claims description 19
- 238000011049 filling Methods 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- -1 pan Substances 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims description 5
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical group CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 5
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 claims description 5
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 5
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 125000005456 glyceride group Chemical group 0.000 claims description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 4
- 241000331598 Trombiculidae Species 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 241000242594 Platyhelminthes Species 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 238000011161 development Methods 0.000 claims description 2
- 238000004945 emulsification Methods 0.000 claims description 2
- 238000000227 grinding Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 1
- 238000010411 cooking Methods 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 150000002314 glycerols Chemical class 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 239000007800 oxidant agent Substances 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 125000005457 triglyceride group Chemical group 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 8
- 210000004369 blood Anatomy 0.000 abstract description 8
- 230000003078 antioxidant effect Effects 0.000 abstract description 3
- 244000000013 helminth Species 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical class C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 abstract 1
- FXWHFKOXMBTCMP-WMEDONTMSA-N milbemycin Chemical class COC1C2OCC3=C/C=C/C(C)CC(=CCC4CC(CC5(O4)OC(C)C(C)C(OC(=O)C(C)CC(C)C)C5O)OC(=O)C(C=C1C)C23O)C FXWHFKOXMBTCMP-WMEDONTMSA-N 0.000 abstract 1
- 235000019197 fats Nutrition 0.000 description 22
- 241000282472 Canis lupus familiaris Species 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 230000005855 radiation Effects 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 208000030852 Parasitic disease Diseases 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000004575 stone Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 235000007516 Chrysanthemum Nutrition 0.000 description 2
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical class CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 241000282849 Ruminantia Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 208000005448 Trichomonas Infections Diseases 0.000 description 2
- 206010044620 Trichomoniasis Diseases 0.000 description 2
- OKTJSMMVPCPJKN-YPZZEJLDSA-N carbon-10 atom Chemical compound [10C] OKTJSMMVPCPJKN-YPZZEJLDSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229940116364 hard fat Drugs 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 150000002943 palmitic acids Chemical class 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 239000000473 propyl gallate Substances 0.000 description 2
- 235000010388 propyl gallate Nutrition 0.000 description 2
- 229940075579 propyl gallate Drugs 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical class C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- VBCFHWSPNHEYGE-UHFFFAOYSA-N 2,3,4-trimethylquinoline Chemical compound C1=CC=C2C(C)=C(C)C(C)=NC2=C1 VBCFHWSPNHEYGE-UHFFFAOYSA-N 0.000 description 1
- GMZLALYCWQSOQS-UHFFFAOYSA-N 2-butylquinoline Chemical group C1=CC=CC2=NC(CCCC)=CC=C21 GMZLALYCWQSOQS-UHFFFAOYSA-N 0.000 description 1
- 239000005660 Abamectin Substances 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 241001465677 Ancylostomatoidea Species 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- 244000180278 Copernicia prunifera Species 0.000 description 1
- 235000010919 Copernicia prunifera Nutrition 0.000 description 1
- 241001137251 Corvidae Species 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical class OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- 208000006968 Helminthiasis Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 244000147568 Laurus nobilis Species 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000002163 Mesapamea fractilinea Species 0.000 description 1
- 241000243789 Metastrongyloidea Species 0.000 description 1
- 208000000291 Nematode infections Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 240000005578 Rivina humilis Species 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 244000297179 Syringa vulgaris Species 0.000 description 1
- 235000004338 Syringa vulgaris Nutrition 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- GPWDPLKISXZVIE-UHFFFAOYSA-N cyclo[18]carbon Chemical compound C1#CC#CC#CC#CC#CC#CC#CC#CC#C1 GPWDPLKISXZVIE-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 150000002027 dodecanoic acid esters Chemical class 0.000 description 1
- 244000078703 ectoparasite Species 0.000 description 1
- 206010014881 enterobiasis Diseases 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000005242 forging Methods 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000003077 lignite Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 150000002790 naphthalenes Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 150000002888 oleic acid derivatives Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 208000014837 parasitic helminthiasis infectious disease Diseases 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 206010039766 scrub typhus Diseases 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical group OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
201696 A6 B6 五、發明說明() 大分子,如 LL-F28249 α-λ 化合物,LL-F28249 α — λ化合物之23 —氧基和23 —亞胺基.的衍生物,米伯徽素化 合物與阿弗徽克素化合物,對溫血動物Μ非經腸給藥時, 對於感染和由孀蟲、線蟲、恙蟲、和體内及體外寄生之節 足動物所引起之寄生蟲感染的預防及治療有效。非經腸給 藥的姐合物在投藥給動物前,要先滅菌消毒。在除去微生 物污染時|加馬射線是一個有效的滅菌步驟。可是某些大 分子,如 LL-F28249 α — λ# 合物 'LL-F28249 α — λ 化 合物之23 —氧基和23 —亞胺基的衍生物,米伯緻素化合物 和阿弗徽克素化合物在放射線照射時 > 會退化及損失很多 生物活性。此種對加馬射線所產生的退化及破壞的反應, 妨礙了我們利用加馬射線來當作消毒某些*如上述之大分子 姐合物。 ... 本發明的一涸課題,即是要提供安定组合物,使該姐合 物經放射線照射後,對溫血動物Μ非經腸給藥時,對於感 染及由孀蟲、線蟲、恙蟲和體内及體外寄生之節足動物所 引起之寄生蟲慼染的預防及治療有效。 本發明的另一課題•是提供一種引人及維持LL-F28249 α — λ化合物,LL-F 28249 α — λ化合物之23—氧基和 23—亞胺基的衍生物,米伯黴素化合物與阿弗徽克素化合 物在溫血動物的血中濃度的方法,使其延長作用時間。 本發明說明了安定微球髑姐合物可Μ為了非經腸給藥而 以放射線照射滅菌。此姐合物包含了,以重量為準,約 20%至95%的脂肪,蟠,或其混合物;約1%至50%之 (請先閲讀背面之注意事項再填穽本页) •裝_ .打. 甲 4(210X297 乂沒) 201696 A6 B6 五、發明说明() - 」 LL-F28249 α — λ 化合物,LL-F28249 α — λ 化合物之 23-氧基和23—亞胺基的衍生物,米伯黴素化合物或阿弗 嫌克素化合物;約1%至30%的油’半軟脂肪,脂肪酸衍 生物,或其混合物;和約0.05%至10%的抗氧化劑。 令人驚訝的是,發琨本發明之微球體姐合物可以藉由加 馬射線來滅菌消毒,而沒有生物活性退化的現象發生。 本發明的安定微球體姐合物,可藉由分散於藥劑及藥理 上可接受的液態賦型劑中,非緝腸給藥。本發明也有 緩慢釋放型的微球體姐合物,分散於藥劑及藥理上可接受 之液態賦型劑中。本發明也包含了一種引入及维持 LL-F28249 α - λ 化合物,LL-F2824a a — λ 之 23—氧基 及23—亞胺基的衍生物,米伯»素化合軚或阿弗激克素化 合物在溫血動物的血中濃度的方法,.使其延長作用時間。 本發明中較佳的安定微球雅姐合物,包含了以重量為準 ,約50%至90%的脂肪,撖·或其混合物;約5%至25% 之 LL-F28249 α — λ 化合物,LL-F28249 α — λ 化合物之 23 —氧基和23 —亞胺基的衍生物,米伯緻素化合物或阿弗 徽克素化合物;約1%至20%的油,半軟脂肪,脂肪酸衍 生物,或其混合物;和約1 %至5 %的抗氧化劑。 所謂LL-F28249 ct — λ化合物(集合名稱),是由微生 物,暗藍灰鐽徽菌之亞種,非產藍鐽級菌的發酵培養液中 分離得到的,乃由美國北部地區研究實驗所沈所得,其 沈澱物編號為第1 5773號。 此LL-F28249 α — λ化合物之结構式如下: 甲 4(210X 297公沒) ...................................^ ...............51..............................^........^ .................. {請先閱讀背面之注意事項再填寫本页) 201696 五、發明说明() A6 B6
(請先閱讀背面之注惫事項再填寫本頁) .装.
LL-P28249a-A •Λ· .蟓. 甲 4 (210X297 公沒) t 201696 A6 B6 五、發明议明() LL-F2«2 4 9. 过薛 . S·,%,0 ^ . .kHssgS£ ':啓薛 2ύ Χ^-Μ· yr'· csicnu) 2ri-^wu CH<CHj)2=a3su G-ipfeci ) 233* 2f 2 cl--一聃 s(CH-2一~3敝 w CH c-,bw
s OH ---^ -κ 力一 =Ρ1Κ eIts3)2 cw^-^CHU-^owu-is CH^--CH-ii 2---¾
Kw H » S3suw w w » sis 】【*a «
«B osmowwn' ^S\^*S3 Ξ CH3-3 oH'l-w 2Uη- * ο»ω·3ίδ r S3 Hll } CKulickw_一- a . CHullll as cliu-aiii cwCJ-a^i cwu>-5.is clurnlK oJur-:st oww ---.§ω_ρ M- .0« »
丨olcw> 丨-5SBKCW—CW 2 —o—cwlo丨-3»K0WI0W 丨0丨CHM φ K ¥ s—s cw—cw —0—OWM-a.fiJinHICW lolcaK>-=>tJS CK—CW —O—CWMIlls K c=c»zi —0—OWN K K os—nw 丨olcslo— -p e » c« 丨 CH J5 Oslo» 丨 olcalo-=«fttCK—CH »、
Ala M丨c CH=C ziss; Cs=ctss-M c«=c z-i.»*»nwnn N- K K CIIHCtNssi CH=Ccss te Η MOJIlCH CH=C Z- si; CH=C Z, s K CH=C Z, s M· osnoCNSas 6 (請先閑讀背面之注意事項再填窝本页) •竦. 甲 4(210X297 公发) 201696 A6 B6 五、發明說明() 在本發明的安定微球體姐合物中,有效的LL-F28249 α 一 λ化合物之23—氧基和23—亞胺基的衍生物,在美國專 利書第4,916,154號中已揭示,在此合併提出參考之。 在本發明的微球體姐合物中,一個較佳的LL-F28249 <α 一 λ化合物和LL-F28249 α — λ化合物之23—亞胺基衍生 物之结構式如下:
以及 23— (鄰一甲肟)F28249 α
_-7 - 甲 4(210X 297r 沒) (請先聞讀背面之注意事項再填寫本頁) *装. •打· ,線· 201696 A6 __B6_ 五、發明說明() -." / * 適用於本發明之姐合物的蟠和脂肪,一般說來,熔點要 高於40¾。本發明所指的蟠,可依哈雷的簡明化學字典第 11 版(Hawley’s The Condensed Chemica丨 Dictionary 11th Edition)定義為一高分子量,低熔點之有機混合物 或化合物,在室溫下為固體,除了不含甘油酯外,與油和 脂肪的姐成類似。有些是碳氫化合物,其他則是脂肪酸和 醇類化合成的酯類。這些化合物包括了飽合或不飽合的長 鐽碳10到碳24的脂肪酸,酵,酯,鹽,醚,或其混合物。 歸於脂類。蛾具有熱塑性,但既然他們不是高分子聚合物 *則不羼於塑膠。一般的性質是與水互相排斥;構造平滑 ;無毒性;沒有難看的顔色及惡臭;易燃且具良好電煤質 的性質。可溶於大部分的有機溶劑中,吼時不溶於水。主 要的型式如下: I ·天然: 1. 動物性(蜂蟠、羊毛脂、蟲漆熥、白蠘) 2. 植物性(巴西棕櫚、堪特利拉、月桂、甘蔗) 3. 確物性: .⑻化石或泥土蝋(地蝤、純地蟈、褐煤锻)。 心油撖(石锢、微晶石锄)(疏鬆石蟈、鱗狀蟠) I ·合成: 1.烯類聚合物和多元醇醚一酯(碳蝤) 2 .氯化萘(鹵素撖) 3.fe;由費照一特洛普司(Fischer — Tropsch )法合成 之碳氫化合物。 甲4(210X 297公匁) (請先«讀背面之注意事項再填其本頁) •装· ♦ A6 B6 201696 五、發明説明() 本發明中所指之脂肪可依哈雷的簡明化學字典第11版定 義為一種高鈒脂肪酸的甘油酯,如硬脂酸酯和棕櫚酸_ ° 此等酯類及其混合物在室溫下是固雅,且具有結晶結構。 如豬油和蠟油。”脂肪〃通常特別指三酸甘油酯,而w脂 質〃則是涵蓋了全部。 脂肪以長鏈碳10 —碳24之脂肪酸的一、二或三酸甘油酯 最佳。此等一、二或三酸甘油酯大多是由硬脂酸•酯,棕櫊 酸酯,月桂酸酯,亞油酸酯,亞麻酸酯,油酸酯和其他, 及其混合物構成,熔點高於50¾較佳。甘油三硬脂酸酯是 最佳的脂肪。除此之外,脂肪酸的親脂性鹽類也很適合, 如硬脂酸鎂及其類似物。 - 本發明所指的油,半軟脂肪,脂肪酸衍*生物,是當成作 用劑,可溶於熔融的硬脂肪中,在該培融之硬脂肪或蠟微 粒化後,於室溫或接近室溫下,加速硬脂肪结晶的物理轉 變,由較不穗定的型式,變為較穩定的型式。此油或半軟 脂肪可以包括混合物或相當純的一、二或三酸甘油酯,最 好是短到中碳鏈的脂肪酸,即是碳2到碳1 8。半軟脂肪與 甘油酯比較起來,具有室溫或近於室溫的熔點。脂肪酸的 衍生物包含了短至中碳鐽之脂肪酸、酵、酯、醚、鹽,或 其混合物。甘油和半軟脂肪特別合適,因為他們是身體的 物理姐成,與生物相容及可被生物分解。 本發明所指之抗氧化劑,可依哈雷的簡明化學字典第 11販定義為一有楗化合物,可加入橡膠,自然的脂肪和油 ’食物產品,汽油和潤滑油中,可分別地減媛氧化,荽質 f 4(21〇X297H) ................................... ...............«-..............................打........-..................终 {請先閱讀背面之注意事邛再填寫本页) 201696 A6 B6 五、發明說明() ,腐敗和膠化。橡膠的抗氧化劑,一般是芳香胺,如二一 冷一萘基一對一苯二胺和笨一 /3 —.蔡胺。許多抗氧化劑可 由酚類化合物(丁基化羥基茴香醚|二一四丁基一鄱一甲 酚,和丙基五倍子酸酯)政代。食品的抗氧化劑在棰低的 量時即有效而且不只能減緩腐敗,遢能藉由減少维他命和 必箱脂肪酸的分解來保持營養的價值。 令人驚訝的是,本發明之抗氧化劑容許微球想組合物以 加馬射線滅菌消毒,並維持其貯架期而無明顯生物活性損 失。如果沒有抗氧化劑存在*大分子,如LL-F28249 α — λ化合物,LL-F28249 α — λ化合物之23 —氧基和23—亞 胺基的衍生物,米伯徽素化合物或阿弗.嫌克素化合物在放 射線照射時會退化,損失很多生物活性適合用於本發明 之微球體姐合物的抗氧化劑包括了丁基化羥基甲苯,丁基 化羥基茴香醚.,四级丁羥基喹啉、丙基五倍子酸酯,α — 維他命Ε ,6 _乙氧基一1·,2 —二氮一 2 ,2 ,4 一三 甲基喹啉,其中丁基化羥基甲苯的類似物是較佳的抗氧化 劑。 本發明之安定微球體分散在藥劑和藥理上可接受的液體 中’可得適用於非經腸給藥之緩慢釋放的姐合物。此賦型 劑可以是水相或油相的嫒衝糸统。油相系统可由動物或植 物或合成而得。較佳的油相賦型劑包含了中.性的一,二或 三酸甘油酯的液賴或其混合物。所謂中性油,是指沒有包 含殘餘酸的油。適用於本發明姐合物的賦型劑堪包括了水 相系统,如緩衝之生理食鹽水;有機溶劑,如甘油和醇; 10 (請先聞讀背面之注意本項再填寫本頁) •訂· 甲 4(210X 297 i沒) 201696 A6 B6 五、發明说明() 和與水不相溶的液體,如油。視所投予之主成分的溶解度 而定。 如界面活性劑,鹽,緩衝劑,或其混合物等之賦型劑可 Μ包含在本發明的姐合物中。如前述之賦型劑用於本發明 時,其用量可為重量之0.1 %至20%。 可將此發明之姐合物溶於適當的賦型劑中,注射到動物 體内,來獲得且維持LL-F28249 α — λ化合物,, LL-F28249 α — λ化合物之23 —氧華和23—亞胺基的衍生 物*米伯辑素化合物或阿弗徵克素化合物的血中湄度,使 其延長作用時間。 維持血中主要活性化合物的濃度·是與保護和治療溫血 動物抵抗感染及由蠕蟲、線蟲、恙蟲和限内及體外寄生之 節足動物所引起之寄生蟲慼染有關。.维持血中濃度是主成 分緩慢釋放之指標。本發明包含了在此所說之姐合物的使 用,來引入及维持LL-F28249 α — λ化合物,LL-F28249 α — λ化合物之23 —氧基和23—亞胺基的衍生物,米伯激 素化合物或阿弗黴克素化合物在動物體内血幹的濃度。 當Μ非經腸給藥時,本發明之组合物對保護或治療溫血 動物,如狗、猫、牛、綿羊、馬、豬、山羊、家禽、及他 類似動物對抗感染和由蠕蟲、線蟲、恙蟲及體内和體外寄 生之節足動物所引起之寄生蟲感染非常有效。 蠕蟲病是一種傳布很廣的疾病,可Κ在許多動物身上看 到,而且會引起世界性之經濟損失。在攞蟲中,最常碰到 的是線蟲。該等線蟲,可在動物體的腸道,心臟、肺、血 (請先W讀背面之注意事項再填寫本页) _^. •打. 甲 4 (210X297 公沒) _- 11 - 201696 A6 B6 五、發明説明() 管和其他身體姐織中發現。首先在受感染的動物身上會引 起貧血,體重減輕及營養不良的現象。對所寄居的器官壁 和組織會造成嚴重的傷害,如果該線蟲未經治療,就雔開 寄居地,可能會導致該感染動物的死亡。 在反芻動物的感染因子中,最常發現的線蟲包括了捻轉 甭蟲及牛胃蟲,通常可在皴戽中發現;庫柏毛樣線蟲•毛 樣線蟲和细頸毛樣線蟲,可在腸道中發現;肺蟲可在肺中 發現。在非反芻動物中,重要的線逯包括了在狗腸道中的 蛔蟲及鈎蟲,心臓中的心絲蟲;豬腸道中的姻蟲;家禽腸 道中的蛔蟲及盲腸蟲;及馬體内的大、小圓蟲。治療動物 來避免上述線蟲之寄生感染•或降低或控制這些感染因子 在動物體內增生,是本發明一個声要且欲^達到的優點。 除了控制蟠蟲及線蟲外,本發明#腔制了節足動物體内 寄生的感染,如牛的食物,和體外寄生的感染,如疥癖。 本發明的微球體可由將主成分,抗氧化劑及其他熔融的 脂肪,撖,或其混合物,加上油*半軟脂肪,脂肪酸衍生 物,或其混合物混合之。再以各種不同的技術,例如利用 乳化或微粒化來使混合物形成微球體,或是利用機械來處 理各成份與熔融的脂肪,撖,或其混合物的混合物並冷卻 之。例如利用離心圓盤。主成分,抗氧化劑,賦型削和脂 肪,锄,或其混合物和油所形成的混合物,也可冷卻成固 賭,然後經過如研製、磨碎、或其類似方法來處理。此微 球體,也許稱為脂肪性微球體較適合,其直徑可達1000微 米,平均粒子大小的範團由25微米至300微米較適合用在 {請先聞讀背面之注意事項再填駕本页) .装· .訂· •綠. 甲 4(210X297 公沒) _-12 - A6 B6 五、發明说明() -., 201696 非經腸給藥中。 \ 為了加強對本發明的了解,下面的幾個例子,是在舉例 說明較多特別的细節。除了定義於申請專利範圍中外本 發明並不局限於此。 例1 :製備K非經賜給藥之23—(鄰一甲后)—F 28249 α之微球體 將甘油二硬脂酸醋(72.8克)和三酸甘油克)置 於燒杯中,在加熱板上加熱p85— 9^c,加入Μ—(鄰一 甲肟)一F 28249 α (12.0克)和丁基化羥基甲苯(1 1 克),而且不斷攢拌之,直到23 — (鄰一甲肟)一F 28249 ot和丁基化羥基甲苯溶解。然後將此溶液倒入實驗 室的噴霧流體器输送皿中。输送皿,输落線,空氣供給線 和一個雙流噴霧微粒噴口都Μ熱空氣滩持在85至90 °C。藉 .二 ~ 著一個1磅1平方吋的壓力頭來输送流體。已微粒化之混 合物由旋風離析器的造流髏室的排出口收集。然後將此微 球體過篩,除去大於180微米的微球體。將那些大於180 微米的微球體收集起來再循環處理。 由上述步驟得到之微球傾有下列姐成: 23—(鄰一甲肟)一F28249a 甘油三硬脂酸酯 三酸甘油 重量百分比 12.0 78.2 (請先《讀背面之注意事項再填穽本頁) ,裝· •打_ .綠. -13 ---— ' Ϋ 4(210X297 公沒) A6 B6 201696 五、發明說明() 丁基化羥基甲苯 j i 例2 :照射後之微球體的安定性 將列於下方之微球體姐合物置於20奄升的血清小瓶中, 取其中兩小瓶Μ乾堞氮氣沖刷Μ除去氧氣。將小瓶Μ彈性 中隔密封,並Μ鋁帽摺叠起來。接著將此微球體在室溫下 ,用鈷60 (加馬射線)依表I的劑量照射之。勝此微球體 以乙腈/水(1:1)萃取,且用藏效液相色譜來分析 » —
2 3—(鄰一甲肟)一F28249 α。其實驗結果摘要如下表I {請先閱讀背面之注意事項再填寫本瓦) 成分 2 3 —(鄰一甲肟) F28249 a 甘油三硬脂酸酯 中碳鏈之三酸甘油 丁基化羥基甲笨 微球辱姐合物* A、... 璽量百分比 重量百分比 12.0 12.0 79 . 78 訂. 0 -緣. 註1 .:依例1 .的步驟製得,但沒有加入丁基化羥基甲基。 2.:依例1.的步驟製得之微球體姐合物。
表I 14 T 4 (210X297 公沒) 201696 A6 B6 五、發明說明() 經故射線照射後夕徼过鵲姐合物2.? — (鄱一甲肟)— F2824Qa之冋復苒分hh 姐成 A B 暴露 空氣 氮氣 空氣 氮氣 (m r a d ) β 〇 94.5 94.5 ,96.5 96.5 0.55 68 . 5 92.5 95.0 96.5 2.1 27.5 90 . 5 96 . 0 95.0 此實驗說明了沒有加入丁基化P基甲笨的微球體,當以 加馬射線照射時|其主成分不論是在空氣或氮氣中都會退 一 化,而有加入丁基化羥基甲笨者則安定。 例3 :本發明之姐合物在狗體内之持績性釋放 將狗每3或4隻分為一姐。在整個試驗中,所有的狗都 餵Μ同量的食物。將狗秤重後•取由例I中所得之微球體 姐合物1克與2.5 %的甲基纖維素在普通生理食鹽水溶液 (2毫升)中混合,注射入狗體內,必須達到每公斤狗體 重之主成分劑量。狗血中所含有之23 — (鄰一甲肟)一 F28249 α的濃度定期以高效液相色譜偵測。此實驗的結果 總结於下表I中,說明了本發明之姐合物對引入及維持 23—(鄰一甲肟)一F28249cx的血中濃度的有效性。 ...................................^ ...............^..............................^........^...................^ {請先聞讀背面之注意事項再填寫本页) 甲 4(210X297 公发) 201696 A6 B6 五、發明说明() 表I 拘的啻賒中,N高效液相色譜測洱之2 3 — ( Μ —甲肟)一 F28249a之平ferfn想灌麽/ 時間 劑量(奄克/公斤) 夭齡___1 . 72 1 111 39 3 197 * •'S^ , 80 8 340 100 15 133 50 21 80 29 28 68 ,21 3 5 51 ... 14 42 33 10 49 20 7 1 二 隻狗 2四 隻狗 (請先閲讀背面之注意事項再填寫本頁) .¾. .打. •線. _-16- 甲 4(210X 297 公沒)
Claims (1)
- 4·、》> Γ.'ιΑ 公 \:ί Α7 Β7 C7 D7 六、申請專利範面 1. 一種用於預防或治療溫血動物中因蟠蟲、線蟲、恙蟲和 體内及體外寄生之節足動物所引起之傳染及感染之B藥 姐合物,係呈微球體形式,其包含K重量計,約20%至 9 5%的由高级脂肪酸之甘油酯姐成之脂肪,蟠*或其混 合物;約 1% 至 50% 自 LL-F28249cr - λ,LL-F28249 α —λ之23 —氧基或23 —亞胺基衍生物,彼等之衍生物及 混合物姐1之群選出之化合物;約1 %至30%的油,半 软脂肪,脂肪酸衍生物,或其混合物;約5%至10% 的抗氧化劑;和約0%至20%的界面活性劑,鹽,緩衝 劑,或其混合物;其中該油或半軟脂肪係由含C2-ie脂 肪酸之甘油酯姐成。 2. 根據申請專利範園第1項之醫藥姐合物,其中該化合物 是選自 23-(鄰一甲肟)-F28249 α 及 LL-F28249 c(組 成之群,該脂肪是甘油三硬脂酸酯*油是中性三酸甘油 ,氧化物是丁基化羥基甲苯,且其中微球體姐合物之平 均粒子大小由約25微米到300微米之中。 3. 根據申請專利範園第1項之Β蕖姐合物,用於非經腸給 藥及緩慢釋放型時,則此微球體須分散在藥劑和藥理上 可接受之液態賦型劑中。 4. 一種製備申請專利範園第1項之《藥姐合物之方法,其 特徴為: 經濟部中央揉準局印製 (請先閱讀背面之注意事項再填荈本頁) 訂· ⑶將約 1 :« 至 50 X的自 LL-F28249 α — λ,LL-F28249 α - λ 之23 -氧基和23 —亞胺基衍生物,彼等之衍生物 或混合物姐成之群邇出之化合物,與約0.05¾:至10J!的抗 T4(210X297 公廣) 201696 A7 B7 C7 D7 力、申請專利範面 氧化劑,及0 %至20%的界面活性劑、鹽、娌衝劑、或 其混合物,與約20%至95%的熔融脂肪、蟠、或其混合 物混合之, (b〗將油,半炊脂肪,脂肪酸衍生物,或其混合物混合而 形成熔融混合物· ⑵箱由乳化.蓀化,或離心豳盤化該熔融混合物而形成 微球體;冷卻該培融混合物,再研製或磨碎此冷卻混 合物而形成嫌球》。 5 .根據申請專利範園第4項的方法,在此,步驟⑻和可 同時進行。 ...................................„ ...............St..............................ίτ (請先«I讀背面之注意事項再蜞荈本頁) 綠 蛆濟部中央橾準扃印裝 2 甲 4(210X297 公廣)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73443091A | 1991-07-23 | 1991-07-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201696B true TW201696B (zh) | 1993-03-11 |
Family
ID=24951666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW081103831A TW201696B (zh) | 1991-07-23 | 1992-05-16 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6340671B1 (zh) |
| EP (1) | EP0525307B1 (zh) |
| JP (1) | JP3470904B2 (zh) |
| KR (1) | KR100235550B1 (zh) |
| CN (1) | CN1046852C (zh) |
| AT (1) | ATE134873T1 (zh) |
| AU (1) | AU651229B2 (zh) |
| BR (1) | BR9202771A (zh) |
| CA (1) | CA2074348C (zh) |
| DE (1) | DE69208765T2 (zh) |
| DK (1) | DK0525307T3 (zh) |
| ES (1) | ES2086022T3 (zh) |
| GR (1) | GR3019234T3 (zh) |
| HK (1) | HK1000005A1 (zh) |
| HU (1) | HU220595B1 (zh) |
| IE (1) | IE74401B1 (zh) |
| IL (1) | IL102567A (zh) |
| MX (1) | MX9204135A (zh) |
| NZ (1) | NZ243619A (zh) |
| TW (1) | TW201696B (zh) |
| ZA (1) | ZA925522B (zh) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5733566A (en) * | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5643595A (en) * | 1992-11-24 | 1997-07-01 | Alkermes Controlled Therapeutics Inc. Ii | Growth promoters for animals |
| DE4308282C2 (de) * | 1993-03-16 | 1994-12-22 | Beiersdorf Ag | Vorzugsweise in Form von Mikrosphärulen vorliegende galenische Matrices |
| DE19613972A1 (de) * | 1996-04-09 | 1997-10-16 | Bayer Ag | Injektionsformulierungen von Avermectinen und Milbemycinen auf Basis von Rizinusöl |
| DE19638045A1 (de) * | 1996-09-18 | 1998-03-19 | Bayer Ag | Injektionsformulierungen von Avermectinen und Milbemycinen |
| US8663692B1 (en) * | 1999-05-07 | 2014-03-04 | Pharmasol Gmbh | Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same |
| BR0010354A (pt) * | 1999-05-07 | 2002-03-05 | Pharmasol Gmbh | Partìculas de lipìdeo à base em misturas de lipìdeos lìquidos e sólidos e método para a sua produção |
| EP1197207B1 (en) * | 2000-10-10 | 2008-04-23 | Wyeth Holdings Corporation | Stable compositions for parenteral administration |
| FR2852843B1 (fr) | 2003-03-24 | 2008-05-23 | Karim Ioualalen | Systeme galenique permettant le masquage du gout |
| NZ534939A (en) * | 2004-08-26 | 2007-04-27 | Bomac Research Ltd | Injectable formulation comprising an anthelmintic compound with complexing compound for improved solubility |
| BR112012008185A2 (pt) | 2009-10-07 | 2016-08-16 | Wyeth Llc | composições que compreendem adjuvante, macrolídeo e antígeno proteináceo, e métodos para uso dessas composições |
| ITUB20153652A1 (it) | 2015-09-16 | 2017-03-16 | Fatro Spa | Microsfere contenenti lattoni macrociclici antielminitici |
| WO2018189314A1 (en) | 2017-04-13 | 2018-10-18 | Ceva Sante Animale | Composition for treating worms infestations |
| KR20220013540A (ko) | 2019-02-21 | 2022-02-04 | 크로마덱스 아이엔씨. | 니코틴아미드 리보사이드, 니코틴산 리보사이드, 환원 니코티닐 리보사이드 화합물, 및 니코티닐 리보사이드 화합물 유도체의 제형에서의 용도 |
| WO2020225143A1 (en) | 2019-05-03 | 2020-11-12 | Intervet International B.V. | Injectable pharmaceutical compositions and uses thereof |
| WO2021233967A1 (en) | 2020-05-20 | 2021-11-25 | Intervet International B.V. | Injectable pharmaceutical compositions and uses thereof |
| WO2022263505A1 (en) * | 2021-06-16 | 2022-12-22 | Société des Produits Nestlé S.A. | Methods of solid phase wax coating of an active ingredient |
| WO2024003291A1 (en) | 2022-06-30 | 2024-01-04 | Virbac | Deslorelin use in chemical castration of a non-human mammal related to pk/pd interaction |
| WO2025190964A1 (en) | 2024-03-12 | 2025-09-18 | Virbac | Parenteral modoflaner for the control of ectoparasites |
| WO2026024600A1 (en) | 2024-07-22 | 2026-01-29 | Zoetis Services Llc | Isoxazoline and macrocyclic lactone microspheres |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3659022A (en) * | 1967-11-13 | 1972-04-25 | Upjohn Co | Methods of preventing impregnation |
| US4144352A (en) * | 1977-12-19 | 1979-03-13 | Merck & Co., Inc. | Milbemycin compounds as anthelmintic agents |
| US5106994A (en) * | 1984-06-05 | 1992-04-21 | American Cyanamid Company | Agents and method of production thereof |
| US5169956A (en) * | 1984-06-05 | 1992-12-08 | American Cyanamid Company | Macrolide antibiotic compounds |
| ATE74009T1 (de) * | 1986-08-11 | 1992-04-15 | American Cyanamid Co | Zusammensetzungen zur parenteralen verabreichung und deren verwendung. |
| GB8803836D0 (en) * | 1988-02-18 | 1988-03-16 | Glaxo Group Ltd | Compositions |
| DE69007515T2 (de) * | 1989-02-28 | 1994-11-03 | American Cyanamid Co | Bolus mit lang andauernder Wirkstoffabgabe, wirksam bei der Prophylaxe, Behandlung oder Bekämpfung des Befalls bei Wiederkäuern durch Fadenwürmer, Milben und Endo- und Ektoparasiten. |
| US5213810A (en) * | 1990-03-30 | 1993-05-25 | American Cyanamid Company | Stable compositions for parenteral administration and method of making same |
| US5192546A (en) * | 1991-01-15 | 1993-03-09 | Mycogen Corporation | Synergistic pesticidal compositions |
| US5346698A (en) * | 1991-01-15 | 1994-09-13 | Mycogen Corporation | Synergistic pesticidal compositions |
| US5185108A (en) * | 1991-07-10 | 1993-02-09 | The B. F. Goodrich Company | Method for producing wax microspheres |
| JP4654917B2 (ja) | 2006-01-12 | 2011-03-23 | 日産自動車株式会社 | 車体後部構造 |
-
1992
- 1992-04-29 EP EP92107277A patent/EP0525307B1/en not_active Expired - Lifetime
- 1992-04-29 AT AT92107277T patent/ATE134873T1/de active
- 1992-04-29 DK DK92107277.3T patent/DK0525307T3/da active
- 1992-04-29 DE DE69208765T patent/DE69208765T2/de not_active Expired - Lifetime
- 1992-04-29 ES ES92107277T patent/ES2086022T3/es not_active Expired - Lifetime
- 1992-05-16 TW TW081103831A patent/TW201696B/zh not_active IP Right Cessation
- 1992-06-30 CN CN92105395A patent/CN1046852C/zh not_active Expired - Lifetime
- 1992-07-15 MX MX9204135A patent/MX9204135A/es unknown
- 1992-07-20 JP JP21325992A patent/JP3470904B2/ja not_active Expired - Lifetime
- 1992-07-20 BR BR929202771A patent/BR9202771A/pt not_active Application Discontinuation
- 1992-07-20 NZ NZ243619A patent/NZ243619A/en unknown
- 1992-07-21 IL IL10256792A patent/IL102567A/en not_active IP Right Cessation
- 1992-07-21 CA CA002074348A patent/CA2074348C/en not_active Expired - Lifetime
- 1992-07-22 ZA ZA925522A patent/ZA925522B/xx unknown
- 1992-07-22 KR KR1019920013077A patent/KR100235550B1/ko not_active Expired - Lifetime
- 1992-07-22 AU AU20472/92A patent/AU651229B2/en not_active Expired
- 1992-07-22 HU HU9202404A patent/HU220595B1/hu unknown
- 1992-07-22 IE IE922373A patent/IE74401B1/en not_active IP Right Cessation
-
1994
- 1994-06-22 US US08/263,574 patent/US6340671B1/en not_active Expired - Lifetime
-
1996
- 1996-03-07 GR GR950402159T patent/GR3019234T3/el unknown
-
1997
- 1997-07-09 HK HK97101523A patent/HK1000005A1/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| MX9204135A (es) | 1993-01-01 |
| ATE134873T1 (de) | 1996-03-15 |
| AU2047292A (en) | 1993-01-28 |
| EP0525307B1 (en) | 1996-03-06 |
| KR930001904A (ko) | 1993-02-22 |
| JPH05194211A (ja) | 1993-08-03 |
| CA2074348A1 (en) | 1993-01-24 |
| IL102567A (en) | 1996-10-31 |
| HUT62454A (en) | 1993-05-28 |
| ZA925522B (en) | 1993-04-28 |
| CN1046852C (zh) | 1999-12-01 |
| IL102567A0 (en) | 1993-01-14 |
| IE922373A1 (en) | 1993-01-27 |
| CN1068735A (zh) | 1993-02-10 |
| NZ243619A (en) | 1994-12-22 |
| HK1000005A1 (zh) | 1997-10-03 |
| US6340671B1 (en) | 2002-01-22 |
| IE74401B1 (en) | 1997-07-30 |
| BR9202771A (pt) | 1993-03-23 |
| ES2086022T3 (es) | 1996-06-16 |
| DK0525307T3 (da) | 1996-04-01 |
| AU651229B2 (en) | 1994-07-14 |
| DE69208765T2 (de) | 1996-09-26 |
| HU220595B1 (hu) | 2002-03-28 |
| HU9202404D0 (en) | 1992-10-28 |
| JP3470904B2 (ja) | 2003-11-25 |
| KR100235550B1 (ko) | 1999-12-15 |
| DE69208765D1 (de) | 1996-04-11 |
| GR3019234T3 (en) | 1996-06-30 |
| EP0525307A1 (en) | 1993-02-03 |
| CA2074348C (en) | 2004-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201696B (zh) | ||
| AU2011322255A1 (en) | Inflammatory disease | |
| Shoemaker et al. | Efficacy of a modified live Edwardsiella ictaluri vaccine in channel catfish as young as seven days post hatch | |
| KR102752755B1 (ko) | 구충제 마크로시클릭 락톤을 포함하는 미세구 | |
| TWI333422B (en) | Oral pharmaceutical preparations comprising ion exchange resins with active substance loading and pseudoplastic gel-former thickeners | |
| HK1000005B (zh) | 作经胃肠道以外投给药物的稳定合成物及其应用 | |
| JPH03169812A (ja) | トリアセチンを含む活性持続性注射用処方剤 | |
| BG107038A (bg) | Гелен паразитициден състав | |
| RU2296004C2 (ru) | Микрошарики, содержащие производное плевромутилина | |
| KR20090122466A (ko) | 엔로플록사신 미세캡슐 제형 및 그 제조 방법 | |
| RU2464979C1 (ru) | Препарат для лечения и профилактики послеродового эндометрита и синдрома метрит-мастит-агалактии у свиноматок | |
| JP4221170B2 (ja) | 非経口投与用の安定な組成物及びそれらの使用 | |
| TW200800293A (en) | Benzimidazole non-aqueous compositions | |
| CN104208656A (zh) | 一种维吉尼亚霉素微乳及其制备方法 | |
| KR100904226B1 (ko) | 레시틴 유사유화제를 함유하는 나노좀 형태의 면역증강제및 그의 백신용 조성물 | |
| US20230256056A1 (en) | Sustained release cancer therapeutics formulations | |
| AU2013368956A1 (en) | Novel veterinary pharmaceutical compositions and method for the production thereof | |
| CN1867319A (zh) | 包含生理活性物质的乳化溶液及其制备方法和给药方法 | |
| BR112015014963B1 (pt) | Formulação de suspensão injetável veterinária |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4A | Expiration of patent term of an invention patent |